Literature DB >> 25862867

Clinical and prognostic significance of survivin, AKT and VEGF in primary mucosal oral melanoma.

Oriana Simonetti1, Guendalina Lucarini2, Corrado Rubini3, Raffaella Lazzarini2, Roberto DI Primio2, Annamaria Offidani4.   

Abstract

AIM: To investigate survivin, AKT and VEGF expression in primary mucosal oral melanoma and explore their correlation with clinicopathological features and prognosis. PATIENTS AND METHODS: Twenty malignant primary oral melanomas were immunostained with antibodies against survivin, AKT, VEGF, CD34. Histological parameters and disease-specific survival were related to marker expressions.
RESULTS: Survivin localization was both nuclear and cytoplasmic with a higher expression of nuclear survivin. High melanocyte survivin expression significantly correlated with higher thickness of primary melanoma. A significant positive correlation was found between melanocyte survivin and phospho Akt and VEGF expression. Survivin was significantly associated with the presence of metastasis. High melanocyte survivin and high endothelial VEGF expression were inversely correlated to both overall and disease-specific 5-year survival.
CONCLUSION: Survivin, via AKT and VEGF, seems to play an important role in oral melanoma and could represent an important prognostic marker of melanoma progression. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  AKT; Survivin; VEGF; microvessel density; oral melanoma; prognostic factor

Mesh:

Substances:

Year:  2015        PMID: 25862867

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

Review 1.  Evolving Treatment Approaches to Mucosal Melanoma.

Authors:  Shuai Zhang; Jiaran Zhang; Jun Guo; Lu Si; Xue Bai
Journal:  Curr Oncol Rep       Date:  2022-05-05       Impact factor: 5.945

2.  Tetraspanin CD9 Expression Predicts Sentinel Node Status in Patients with Cutaneous Melanoma.

Authors:  Guendalina Lucarini; Elisa Molinelli; Caterina Licini; Giulio Rizzetto; Giulia Radi; Gaia Goteri; Monica Mattioli-Belmonte; Annamaria Offidani; Oriana Simonetti
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 3.  Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma.

Authors:  Zakir Khan; Abdul Arif Khan; Hariom Yadav; Godavarthi B K S Prasad; Prakash Singh Bisen
Journal:  Cell Mol Biol Lett       Date:  2017-04-05       Impact factor: 5.787

4.  Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial.

Authors:  Xinan Sheng; Xieqiao Yan; Zhihong Chi; Lu Si; Chuanliang Cui; Bixia Tang; Siming Li; Lili Mao; Bin Lian; Xuan Wang; Xue Bai; Li Zhou; Yan Kong; Jie Dai; Kai Wang; Xiongwen Tang; Huaning Zhou; Hai Wu; Hui Feng; Sheng Yao; Keith T Flaherty; Jun Guo
Journal:  J Clin Oncol       Date:  2019-08-12       Impact factor: 44.544

5.  A novel inflammatory response-related signature predicts the prognosis of cutaneous melanoma and the effect of antitumor drugs.

Authors:  Jiahua Xing; Yan Li; Youbai Chen; Yan Han
Journal:  World J Surg Oncol       Date:  2022-08-19       Impact factor: 3.253

Review 6.  Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.

Authors:  Lili Mao; Zhonghui Qi; Li Zhang; Jun Guo; Lu Si
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.